INS and type 2 diabetes mellitus: Moreover, the SURPASS programme demonstrated that tirzepatide 15 mg is more efficacious in glycaemic control for people with T2D compared to insulin therapies as well as GLP-1 mono-agonists including semaglutide 1 mg and dulaglutide 1.5 mg.